![https://img.particlenews.com/image.php?url=0lZHh1_0uS3y1Kn00](https://img.particlenews.com/image.php?type=thumbnail_580x000&url=0lZHh1_0uS3y1Kn00)
NORTH DAKOTA ( KXNET ) — A new genetic screening research study has been launched by Sanford Health.
According to a news release, it’s called ImagineYou, and it’s a partnership with Sanford Imagenetics and Helix.
The study provides genetic screening of conditions with an increased risk for certain cancers and heart disease, and it has no cost.
Conditions it covers include:
- Familial hypercholesterolemia (hereditary high cholesterol)
- Hereditary Breast and Ovarian Cancer Syndrome (BRCA1 and BRCA2)
- Lynch Syndrom (hereditary colon cancer)
Things to do around town: July 15-21 People who participate and show an increased risk will be referred to genetic counseling for a free follow-up. They can also opt-in to learn about their regional ancestry and genetic traits.
“ImagineYou is a unique genetic screening program that will help patients and their care teams identify potential factors that put them at risk for specific conditions later on in their lifetime,” said the Chief Medical Officer at Sanford, Dr. Jeremy Cauwels. “This gives patients an opportunity to learn more about their DNA and help them better understand their personal health risks to help them, along with their primary care provider, plan for a healthier future.”
Everyone who chooses to participate in this study will get updates on the study and its impact.
The information that’s consented to be used confidentially will help researchers study how DNA can impact health, what could cause certain diseases, and learn more about how to treat them.
For more information, and to learn how to enroll, you can visit this website .
Close Thanks for signing up!
Watch for us in your inbox.
Subscribe Now
Today's Top Stories
Copyright 2024 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. For the latest news, weather, sports, and streaming video, head to KX NEWS.
Comments / 0